Norman Fultang

Norman Fultang is a Principal Scientist at Prelude Therapeutics with a strong background in molecular biology and cancer research. With experience at Quanta Therapeutics and the University of Pennsylvania School of Medicine, Norman has characterized novel transcriptional mechanisms in cancer cells and developed potential immunotherapeutic agents. Norman also has experience as a Graduate Student Instructor at the University of the Sciences in Philadelphia, where Norman assisted in the identification of bacteriophages for drug-resistant Tuberculosis. With a Ph.D. in Cell and Molecular Biology, Norman has published multiple peer-reviewed articles and mentored students in research techniques. Norman's expertise spans from cancer drug targeting to therapeutic agent development for flaviviruses.